Artivion, Inc. (FRA:CYL)

Germany · Delayed Price · Currency is EUR

38.80

0.00 (0.00%)

At close: Dec 5, 2025

38.32% (1Y)

Market Cap	1.84B
Revenue (ttm)	360.22M
Net Income (ttm)	-7.77M
Shares Out	n/a
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	56.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	38.80
Previous Close	38.80
Day's Range	38.80 - 38.80
52-Week Range	19.44 - 41.10
Beta	n/a
RSI	50.17
Earnings Date	Feb 20, 2026

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offe... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies

Founded 1984

Employees 1,600

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol CYL

Full Company Profile

Financial Performance

In 2024, Artivion's revenue was $388.54 million, an increase of 9.75% compared to the previous year's $354.00 million. Losses were -$13.34 million, -56.37% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.